Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
IPO Year: 2018
Exchange: NASDAQ
Website: bionanogenomics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/5/2023 | $4.00 | Sector Outperform | Scotiabank |
12/12/2022 | $3.50 | Buy | BTIG Research |
7/18/2022 | $12.00 | Outperform | Oppenheimer |
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
4 - Bionano Genomics, Inc. (0001411690) (Issuer)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G - Bionano Genomics, Inc. (0001411690) (Subject)
SC 13G - Bionano Genomics, Inc. (0001411690) (Subject)
SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of an aggregate of 17,513,136 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.571 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company has also agreed to issue to the investors unregistered clinical milestone-linked warrants, comprising Series A warrants to purchase up
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applicationsTwo scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing applications will be presented at the conference SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation in the International Society for Stem Cell Research (ISSCR) Annual Meeting 2024 with a broad range of content
Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflowVIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE:RVTY) under which Revvity will market and co
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ HemeOne laboratory developed test (LDT) from third party payers. The Category I CPT code is expected to be included in the next CPT codebook and to be effecti
A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applicationsBionano will host a sponsored session at ESHG featuring an overview of the Company's OGM workflow delivered by Bionano's chief medical officer, Dr. Alka Chaubey, a presentation from Dr. Laura Batlle Masó at Vall d'Hebron Institute of Research (Spain) on OGM's potential utility in resolving hereditary angioedema (HAE) cases, a presentation from Dr. Bart
SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024. This new financing reinforces the strategic plan set out by the Company in February 2024, by strengthening its capital structure, improving its liquidity position, and enhancing the Company's ability to c
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer's diseaseTaken together, the publications illustrate that OGM can be highly sensitive for genome-wide detection of on and off target effects that may limit the utility of stem cell lines and CAR-T cell products SAN DIEGO, May 21, 2024 (GLOBE
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company's VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematological diseases. Advancements to the suite of tools include: Enhanced Detection of Critical Variants Improved sensitivity and precision provide increased accuracy for detection of aneu
Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023Efforts to reduce cash burn and operating expense continued with the March 2024 announcement of expanded cost savings initiatives; since the initial cost savings initiative announced in May 2023, the Company plans to have reduced headcount by approximately 200 people by the end of Q2 2024 and to have reduced annualized non-GAAP operating expenses by about $65.0 to $75
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/mmc/p/5z343pph/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor re
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
EFFECT - Bionano Genomics, Inc. (0001411690) (Filer)
424B3 - Bionano Genomics, Inc. (0001411690) (Filer)
S-3 - Bionano Genomics, Inc. (0001411690) (Filer)
D - Bionano Genomics, Inc. (0001411690) (Filer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
S-8 - Bionano Genomics, Inc. (0001411690) (Filer)
10-Q - Bionano Genomics, Inc. (0001411690) (Filer)
8-K - Bionano Genomics, Inc. (0001411690) (Filer)
DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)
QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l
TwinStrand Biosciences, Inc., the pioneer and developer of duplex sequencing, today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer. Dr. Pljevaljcic brings a successful track-record of commercial leadership in the genomics industry to TwinStrand, including experience building and managing clinical and research products through all stages of commercialization. "TwinStrand is pleased to welcome Goran to the team. His experience further solidifies our management team and brings capabilities that will be invaluable as we continue to expand our commercial portfolio of high-resolution duplex sequencing offerings," said TwinStrand CEO Jesse Salk, M.D., Ph.D. "Gor
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the appointment of Aleks Rajkovic, MD, PhD, to its board of directors. Dr. Rajkovic is currently the Chief Genomics Officer at the University of California, San Francisco (UCSF), a Stuart Lindsay Distinguished Professor in Experimental Pathology, and Medical Director and Chief of the Center for Genetic and Genomic Medicine at UCSF Health. Prior to arriving to UCSF, he was the Chief of Medical and L
SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced that it has appointed Helene Klein as its chief people officer, further strengthening its leadership team. As the company expands, culture and employee experience become key success factors. The appointment of a chief people officer today reflects Bionano's focus on maintaining and evolving its culture of innovative, disciplined, and rapid response to market needs. Ms. Klein was formerly the chief people o
SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the appointment of Vincent Wong, JD, MBA, to its board of directors. Mr. Wong is currently the chief commercial officer at Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health. He joined Geneoscopy in March 2021 after almost 18 years at Roche Diagnostics, where he held senior leadership roles across the spectrum of commercial execution, including product
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software for genomic data visualization, interpretation and reporting, today announced that it has appointed Keith Gligorich, PhD, MB(ASCP)cm to the role of VP Operations for Bionano Laboratories. Keith was most recently with Guarant Health where he led the build-out of Guardant's CLIA-certified, CAP-accredited laboratory for blood-based early cancer detection testing. He has over a decade of experience in molecular diagnostic test development and laboratory operations. Prior to joining Guardant Health, Keith held le
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that two former Illumina executives, Stephanie Hoyle and Alex Helm, have joined the Company as vice presidents of Corporate Marketing and Strategic Product Marketing, respectively. Together, they bring 22 years of experience in the genomics space and 36 years of experience in marketing. At Bionano, Stephanie will oversee global marketing and brand strategy for the Company. During her tenure at Illumina, she worked in similar positions and was instrumental in developi
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer. Richard was one of the transformational leaders at Affymetrix who brought microarrays into the clinic and paved the way for the first FDA-cleared application of microarrays in cytogenetics with the CytoScan HD Array developed by Affymetrix. For Bionano, he will be responsible for leading product strategy, broadening its business into new markets and strategic expansion of its product and technology portfolios. "We are thrilled to welcome Rich to Bionano. He adds a highly complementary skillset to our team as we put in p
A sponsored session will feature Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano presenting on the utility of optical genome mapping (OGM) across cell and gene therapy research, development and manufacturing applicationsTwo scientific posters featuring results from OGM applications in cell manufacturing and bioprocessing applications will be presented at the conferenceSAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced its participation in the International Society for Stem Cell Research (ISSCR) Annual Meeting 2024 with a broad range of content cove
Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ HemeOne laboratory developed test (LDT) from third party payers. The Category I CPT code is expected to be included in the next CPT codebook and to be effective January 1, 2025.
Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024.
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer's diseaseTaken together, the publications illustrate that OGM can be highly sensitive for genome-wide detection of on and off target effects that may limit the utility of stem cell lines and CAR-T cell productsSAN DIEGO, May 21, 2024 (GLOBE NEWSW
BTIG analyst Mark Massaro maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and lowers the price target from $3 to $2.
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.65) by 7.69 percent. This is a 51.22 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $8.769 million which beat the analyst consensus estimate of $8.492 million by 3.26 percent. This is a 18.26 percent increase over sales of $7.415 million the same period last year.
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Some of OGM's novel findings, however, are difficult for other methods to validate, because of their resolution limitations. In this paper, researchers used OGM to detect variants in the BMA samples that were missed by traditional methods, and then a
Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00
BTIG Research resumed coverage of Bionano Genomics with a rating of Buy and set a new price target of $3.50
Oppenheimer resumed coverage of Bionano Genomics with a rating of Outperform and set a new price target of $12.00
BTIG initiated coverage of Bionano Genomics with a rating of Buy and set a new price target of $10.00
Oppenheimer reiterated coverage of Bionano Genomics with a rating of and set a new price target of $15.00 from $1.50 previously
LADENBURG THALM/SH SH reiterated coverage of Bionano Genomics with a rating of Buy and set a new price target of $14.00 from $1.25 previously
Maxim Group reiterated coverage of Bionano Genomics with a rating of and set a new price target of $14.00 from $2.00 previously
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/mmc/p/5z343pph/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor re
Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022Reached installed base of 326 optical genome mapping (OGM) systems as of YE 2023; increase of 36% over the 240 installed systems as of YE 2022Sold 26,444 nanochannel array flowcells in FY 2023, which represents a 72% increase over the flowcells sold in FY 2022Conference call today, March 5, 2024 at 4:30 PM ET SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024. "2023 was a year in
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, March 5th, 2024Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/afaym86g/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ("Bionano") (NASDAQ:BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the "Buyer") (i) in a registered offering by the company (a) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 initially convertible by the Buyer into approximately 15.7 million shares of the company's common stock (the "Initial Registered Note"), and (b) warrants to purchase up to 21.7 million shares of the company's common stock, and (ii) in a concurrent private plac
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 8th, 2023Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/xoj2hwr3 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website a
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, August 9th, 2023Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/kdtv69k5 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, May 9th, 2023Time:4:30 p.m. ETLive call:Toll-Free: (800) 715-9871Conference ID: 4068548Webcast:https://edge.media-server.com/mmc/p/tw7qar43 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, March 9th, 2023 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, March 9th, 2023Time:4:30 p.m. ESTLive call:Register here for dial-in number and pinWebcast:https://edge.media-server.com/mmc/p/wi7rgr4x Participants may access a live webcast of the call on the Investors page of the Bionano website. To participate via telephone, please register in advance at this link. Upon registration
Acquisition adds isotachophoresis (ITP), a proprietary technology licensed exclusively from Stanford University and developed by Purigen Biosystems for isolation and purification of nucleic acids, to the arsenal of tools for potentially simplifying ultra high molecular weight (UHMW) DNA isolation and purification for optical genome mapping (OGM) with more consistency at scale Adds the Ionic® Purification System, a commercially available platform for isolation of DNA and RNA from complex biological samples including those with low cell counts or otherwise challenging types such as formalin-fixed paraffin embedded (FFPE) tumor tissue, to Bionano's portfolio of productsAdds a world-class team w
– 55% year-over-year revenue growth in Q3 2022 – On track to achieve all 2022 ELEVATE! milestones – Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022 – Conference call today, November 3rd, 2022 at 4:30 PM ET SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today reported financial results for the third quarter ended September 30, 2022. The Company executed its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of the Saphyr system at leading institutions across the globe, wi